Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,386

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Minor Ischemic Stroke
Interventions
DRUG

rhTNK-tPA

rhTNK-tPA 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds. Additionally, placebo oral aspirin and clopidogrel are given. Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy.

DRUG

Control group (Aspirin combined with clopidogrel)

Dual antiplatelets with aspirin 100mg and clopidogrel 300mg, plus placebo intravenous rhTNK-tPA. Placebo oral aspirin and clopidogrel are administered within 6 ± 2 hours following intravenous placebo.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER